Bronfman E.L. Rothschild L.P. lifted its stake in shares of Danaher Co. (NYSE:DHR) by 6.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,550 shares of the conglomerate’s stock after purchasing an additional 1,517 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Danaher were worth $2,186,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in DHR. GQG Partners LLC bought a new position in Danaher in the 2nd quarter valued at about $101,000. Zions Bancorporation lifted its position in Danaher by 118.3% in the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock valued at $106,000 after acquiring an additional 667 shares in the last quarter. Patten Group Inc. lifted its position in Danaher by 262.3% in the 3rd quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock valued at $114,000 after acquiring an additional 3,497 shares in the last quarter. First Personal Financial Services lifted its position in Danaher by 128.9% in the 4th quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock valued at $114,000 after acquiring an additional 691 shares in the last quarter. Finally, Calton & Associates Inc. bought a new position in Danaher in the 4th quarter valued at about $114,000. 75.88% of the stock is currently owned by institutional investors.
Shares of Danaher Co. (NYSE:DHR) opened at $95.41 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.43 and a quick ratio of 1.05. The company has a market cap of $66,370.00, a PE ratio of 27.26, a price-to-earnings-growth ratio of 1.99 and a beta of 1.04. Danaher Co. has a one year low of $78.97 and a one year high of $104.82.
The business also recently declared a quarterly dividend, which was paid on Friday, January 26th. Stockholders of record on Friday, December 29th were paid a dividend of $0.14 per share. The ex-dividend date was Thursday, December 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.59%. Danaher’s payout ratio is currently 16.00%.
In other news, SVP Angela S. Lalor sold 42,988 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the completion of the sale, the senior vice president now owns 82,008 shares in the company, valued at approximately $8,388,598.32. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Daniel L. Comas sold 62,989 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the sale, the chief financial officer now owns 227,805 shares of the company’s stock, valued at approximately $23,226,997.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 274,913 shares of company stock valued at $27,729,293. 12.20% of the stock is currently owned by company insiders.
Several equities analysts recently weighed in on DHR shares. Robert W. Baird reaffirmed a “buy” rating and issued a $99.00 price target on shares of Danaher in a research report on Friday, December 15th. Citigroup raised their price target on shares of Danaher to $107.00 and gave the company a “buy” rating in a research report on Friday, December 15th. Cowen reaffirmed a “buy” rating and issued a $110.00 price target on shares of Danaher in a research report on Tuesday, January 30th. UBS Group started coverage on shares of Danaher in a research report on Monday, January 22nd. They issued a “buy” rating and a $99.97 price target on the stock. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $110.00 price target on shares of Danaher in a research report on Friday, January 19th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Danaher presently has an average rating of “Buy” and an average target price of $100.13.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2018/02/13/danaher-co-dhr-shares-bought-by-bronfman-e-l-rothschild-l-p.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.